AI Article Synopsis
- The study examined the clinical and survival characteristics of transplant-eligible multiple myeloma patients in Latin America, focusing on the differences between public and private healthcare systems.
- It included data from 1293 patients diagnosed from 2010 to 2018, highlighting significant disparities in outcomes and survival rates between those treated in public versus private institutions.
- The findings suggest that late diagnosis and limited access to effective treatments in public facilities contribute to poorer survival rates, while patients receiving modern therapies and autologous stem cell transplants have survival rates comparable to international standards.
Article Abstract
The aim of this study was to describe clinical and survival characteristics of transplant-eligible multiple myeloma (MM) patients in Latin America (LA), with a special focus on differences between public and private healthcare facilities. We included 1293 patients diagnosed between 2010 and 2018. A great disparity in outcomes and survival between both groups was observed. Late diagnosis and low access to adequate frontline therapy and ASCT in public institutions probably explain these differences. Patients treated with novel drug induction protocols, followed by autologous stem cell transplantation (ASCT) and maintenance, have similar overall survival compared to that published internationally.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2020.1804558 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unmasking Multiple Myeloma: The Importance of Suspecting Malignancy in Atypical Chronic Pain Mimicking Degenerative Conditions-A Case Report.
Clin Case Rep
January 2025
Los Angeles, David Geffen School of Medicine, Department of Anesthesiology and Perioperative Medicine, Division of Pain Medicine University of California Los Angeles California USA.
Heightened clinical vigilance for multiple myeloma is essential in patients presenting with atypical chronic pain progression. Symptoms may overlap with degenerative musculoskeletal conditions, frequently leading to misdiagnosis. This underscores the necessity of a thorough evaluation when symptoms are refractory to conventional therapies, in order to facilitate timely diagnosis and effective management of malignancy.
View Article and Find Full Text PDFIdecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) have revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM), but direct comparisons are lacking. Leveraging an international multicenter RRMM cohort, we compared the outcome of ide-cel ( = 162) versus cilta-cel ( = 42). Co-primary efficacy endpoints of the study were overall response rate (ORR) and progression-free survival (PFS).
View Article and Find Full Text PDFClinical Validation of Optical Genome Mapping in Multiple Myeloma Without Plasma Cell Enrichment.
Am J Hematol
January 2025
Department of Laboratory Medicine, Korea University College of Medicine, Seoul, South Korea.
Enhancing staging in multiple myeloma using an m6A regulatory gene-pairing model.
Clin Exp Med
January 2025
Department of Hematology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, People's Republic of China.
Multiple myeloma (MM) is characterized by clonal plasma cell proliferation in the bone marrow, challenging prognosis prediction. We developed a gene-pairing prognostic risk model using m6A regulatory genes and a nested LASSO method. A cutoff of - 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!